Skip to main content
SpringerLink
Log in

Insulin-Like Growth Factors, Cardiovascular Risk Factors, and Cardiovascular Disease

  • Chapter
Cardiovascular Endocrinology

Part of the book series: Contemporary Endocrinology ((COE))

  • 709 Accesses

Summary

Insulin-like growth factor-1 (IGF-1) is a peptide that is mostly produced in the liver. It was previously thought that IGF-1 could contribute to the development of atherosclerotic and hypertensive vascular disease. However, recent evidence suggests that this is likely not the case, and that IGF-1 may confer a protective role against atherosclerosis. Furthermore, altered IGF-1 levels and/or signaling may play a role in the pathogenesis of heart failure. We hereby review the available clinical data on the role of IGF-1 in cardiovascular disease and its relation to the cardiovascular risk factors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 2004;24(3):435–44.

    Article  PubMed  CAS  Google Scholar 

  2. Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf) 1994;41(1):85–93.

    Article  CAS  Google Scholar 

  3. Colao A, di Somma C, Pivonello R, et al. The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. J Clin Endocrinol Metab 2002;87(3):1088–93.

    Article  PubMed  CAS  Google Scholar 

  4. Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW. Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol 1998;18(2):277–82.

    PubMed  CAS  Google Scholar 

  5. Okura Y, Brink M, Zahid AA, Anwar A, Delafontaine P. Decreased expression of insulin-like growth factor-1 and apoptosis of vascular smooth muscle cells in human atherosclerotic plaque. J Mol Cell Cardiol 2001;33(10):1777–89.

    Article  PubMed  CAS  Google Scholar 

  6. Patel VA, Zhang QJ, Siddle K, et al. Defect in insulin-like growth factor-1 survival mechanism in atherosclerotic plaque-derived vascular smooth muscle cells is mediated by reduced surface binding and signaling. Circ Res 2001;88(9):895–902.

    Article  PubMed  CAS  Google Scholar 

  7. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case–control study. Circulation 2002;106(8):939–44.

    Article  PubMed  CAS  Google Scholar 

  8. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004;89(1):114–20.

    Article  PubMed  CAS  Google Scholar 

  9. Colao A, Spiezia S, Di Somma C, et al. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. J Endocrinol Invest 2005;28(5):440–8.

    PubMed  CAS  Google Scholar 

  10. Bayes-Genis A, Schwartz RS, Bale LK, Conover CA. Effects of insulin-like growth factor-I on cultured human coronary artery smooth muscle cells. Growth Horm IGF Res 2003;13(5):246–53.

    Article  PubMed  CAS  Google Scholar 

  11. Grant MB, Wargovich TJ, Ellis EA, et al. Expression of IGF-I, IGF-I receptor and IGF binding proteins-1, -2, -3, -4 and -5 in human atherectomy specimens. Regul Pept 1996;67(3):137–44.

    Article  PubMed  CAS  Google Scholar 

  12. Grant MB, Wargovich TJ, Bush DM, et al. Expression of IGF-1, IGF-1 receptor and TGF-beta following balloon angioplasty in atherosclerotic and normal rabbit iliac arteries: an immunocytochemical study. Regul Pept 1999;79(1):47–53.

    Article  PubMed  CAS  Google Scholar 

  13. Nichols TC, du Laney T, Zheng B, et al. Reduction in atherosclerotic lesion size in pigs by alphaVbeta3 inhibitors is associated with inhibition of insulin-like growth factor-I-mediated signaling. Circ Res 1999;85(11):1040–5.

    PubMed  CAS  Google Scholar 

  14. Vasan RS, Sullivan LM, D’Agostino RB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med 2003;139(8):642–8.

    PubMed  CAS  Google Scholar 

  15. Bleumink GS, Rietveld I, Janssen JA, et al. Insulin-like growth factor-I gene polymorphism and risk of heart failure (the Rotterdam Study). Am J Cardiol 2004;94(3):384–6.

    Article  PubMed  CAS  Google Scholar 

  16. Anwar A, Gaspoz JM, Pampallona S, et al. Effect of congestive heart failure on the insulin-like growth factor-1 system. Am J Cardiol 2002;90(12):1402–5.

    Article  PubMed  CAS  Google Scholar 

  17. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96(2):526–34.

    PubMed  CAS  Google Scholar 

  18. Hambrecht R, Schulze PC, Gielen S, et al. Effects of exercise training on insulin-like growth factor-I expression in the skeletal muscle of non-cachectic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2005;12(4):401–6.

    Article  PubMed  Google Scholar 

  19. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 1996;97(11):2509–16.

    Article  PubMed  CAS  Google Scholar 

  20. Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 2005;115(2):451–8.

    PubMed  CAS  Google Scholar 

  21. Ranke MB. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance. Trends Endocrinol Metab 2005;16(4):190–7.

    Article  PubMed  CAS  Google Scholar 

  22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15(7):539–53.

    Article  PubMed  CAS  Google Scholar 

  23. Kaushal K, Heald AH, Siddals KW, et al. The impact of abnormalities in IGF and inflammatory systems on the metabolic syndrome. Diabetes Care 2004;27(11):2682–8.

    Article  PubMed  CAS  Google Scholar 

  24. Shigematsu S, Yamauchi K, Nakajima K, Iijima S, Aizawa T, Hashizume K. IGF-1 regulates migration and angiogenesis of human endothelial cells. Endocr J 1999;46 Suppl:S59–S62.

    Article  PubMed  CAS  Google Scholar 

  25. Clemmons DR, Maile LA, Ling Y, Yarber J, Busby WH. Role of the integrin alphaVbeta3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress. Growth Horm IGF Res 2007 Aug; 17(4):265–70. Epub 2007 Apr 6.

    Google Scholar 

  26. Gibson JM, Westwood M, Young RJ, White A. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). J Clin Endocrinol Metab 1996;81(2):860–3.

    Article  PubMed  CAS  Google Scholar 

  27. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 2000;85(4):1518–24.

    Article  PubMed  CAS  Google Scholar 

  28. Saukkonen T, Amin R, Williams RM, et al. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes. J Clin Endocrinol Metab 2004;89(9):4634–41.

    Article  PubMed  CAS  Google Scholar 

  29. Acerini CL, Patton CM, Savage MO, Kernell A, Westphal O, Dunger DB. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997;350(9086):1199–204.

    Article  PubMed  CAS  Google Scholar 

  30. Genovese S, Riccardi G. The role of modulation of GH/IGF-I axis in the development of diabetic proliferative retinopathy. J Endocrinol Invest 2003;26(8 Suppl):114–6.

    PubMed  CAS  Google Scholar 

  31. Wilkinson-Berka JL, Wraight C, Werther G. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Curr Med Chem 2006;13(27):3307–17.

    Article  PubMed  CAS  Google Scholar 

  32. Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 2001;4(4):239–49.

    Article  PubMed  CAS  Google Scholar 

  33. Kajantie E, Fall CH, Seppala M, et al. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-1 in elderly people: relationships with cardiovascular risk factors, body composition, size at birth, and childhood growth. J Clin Endocrinol Metab 2003;88(3):1059–65.

    Article  PubMed  CAS  Google Scholar 

  34. Colangelo LA, Liu K, Gapstur SM. Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and cardiovascular disease risk factors in young black men and white men: the CARDIA Male Hormone Study. Am J Epidemiol 2004;160(8):750–7.

    Article  PubMed  Google Scholar 

  35. Higashi Y, Peng T, Du J, et al. A redox-sensitive pathway mediates oxidized LDL-induced downregulation of insulin-like growth factor-1 receptor. J Lipid Res 2005;46(6):1266–77.

    Article  PubMed  CAS  Google Scholar 

  36. Scheidegger KJ, James RW, Delafontaine P. Differential effects of low density lipoproteins on insulin-like growth factor-1 (IGF-1) and IGF-1 receptor expression in vascular smooth muscle cells. J Biol Chem 2000;275(35):26864–9.

    PubMed  CAS  Google Scholar 

  37. Okura Y, Brink M, Itabe H, Scheidegger KJ, Kalangos A, Delafontaine P. Oxidized low-density lipoprotein is associated with apoptosis of vascular smooth muscle cells in human atherosclerotic plaques. Circulation 2000;102(22):2680–6.

    PubMed  CAS  Google Scholar 

  38. Li Y, Higashi Y, Itabe H, Song YH, Du J, Delafontaine P. Insulin-like growth factor-1 receptor activation inhibits oxidized LDL-induced cytochrome C release and apoptosis via the phosphatidylinositol 3 kinase/Akt signaling pathway. Arterioscler Thromb Vasc Biol 2003;23(12):2178–84.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Islam Bolad MBBS MD MRCP FESC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrice Delafontaine MD FACC FACP FAHA FESC
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Tulane University Health Sciences Center, New Orleans, LO, USA

    Vivian A. Fonseca (MD) (MD)

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Bolad, I., Delafontaine, P. (2009). Insulin-Like Growth Factors, Cardiovascular Risk Factors, and Cardiovascular Disease. In: Fonseca, V.A. (eds) Cardiovascular Endocrinology. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-59745-141-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-141-3_14

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-850-8

  • Online ISBN: 978-1-59745-141-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation